Principal Director The George Institute for Global Health
- Board Member, The George Institute for Global Health
- Professor of Cardiovascular medicine at Sydney University
- Professor of Medicine at Oxford University
Stephen is one of the founders of The George Institute for Global Health, an architect of its global expansion and currently holds the position of Principal Director of The George Institute for Global Health (worldwide).
He also holds professorial appointments in medicine at both the University of Sydney (Australia) and the University of Oxford (UK), where he is a James Martin Professorial Fellow. Stephen is an international authority on the causes, prevention and treatment of cardiovascular diseases and has a special interest is the management of chronic and complex conditions in resource-poor settings, particularly in the Asia-Pacific region.
In addition to his Institute and university appointments, Stephen holds several external appointments, including those as Chair of the International Scientific Board of the UK BioBank. He is also Executive Chair of George Clinical Pty Ltd, a wholly owned subsidiary of The George Institute. He sits on the Boards of several other not-for-profit organisations, including the Oxford Health Alliance.
Stephen has published more than 300 scientific papers and delivered more than 200 invited lectures. For his work in the field of cardiovascular disease, he has received numerous awards, fellowships and honours from various governments, universities and learned societies.
Efficacy and safety of statin therapy in older people: metaanalysis of individual participant data from 28 randomised controlled trials
COLLINS RE. et al, (2019), Lancet
Sex-specific relevance of diabetes to occlusive vascular and other mortality: Meta-analysis of individual data from 68 prospective studies with 77,000 deaths among 1 million adults
Lewington S. et al, (2018), The Lancet Diabetes and Endocrinology
Elevated blood pressure and risk of mitral regurgitation: A longitudinal cohort study of 5.5 million United Kingdom adults.
Rahimi K. et al, (2017), PLoS medicine, 14, e1002404 - e1002404
The Effects of a Community-Based Sodium Reduction Program in Rural China – A Cluster-Randomized Trial
Li N. et al, (2016), PLOS ONE, 11, e0166620 - e0166620
Interpretation of the evidence for the efficacy and safety of statin therapy.
Collins R. et al, (2016), Lancet (London, England)